Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact

Phase 3positiveenvudeucitinibIcotydeOtezlaPositive

AI Analysis

Summary

Alumis achieved Phase III victories with envudeucitinib for psoriasis treatment. However, analysts expressed limited enthusiasm about the commercial impact given competition from established oral psoriasis drugs like Icotyde, Otezla, and Sotyktu.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Alumis achieved Phase III psoriasis pill victories with envudeucitinib

Importance:6/10

Sentiment:

0.30

psoriasisoral medicationPhase 3competitive market

Related Companies

$IBO $TRAX $DMIIR $ARNA

Read the original article

Published by Clinical Trials Arena on October 9, 2026 4:11 PM

Read Original